"10.1371_journal.pone.0070890","plos one","2013-08-22T00:00:00Z","Janna Sand-Dejmek; Roy Ehrnström; Pontus Berglund; Tommy Andersson; Lisa Ryden","Experimental Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden; Surgery, Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Malmö, Sweden; Clinical Pathology, Department of Laboratory Medicine Malmö, Lund University, Skåne University Hospital, Malmö, Sweden; Surgery, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden","Conceived and designed the experiments: JSD TA LR. Performed the experiments: JSD RE PB. Analyzed the data: JSD RE LR TA PB. Contributed reagents/materials/analysis tools: TA LR. Wrote the paper: JSD TA LR.","JSD and TA are shareholders of WntResearch AB. TA is part-time CSO of WntResearch AB. WntResearch AB owns two patents on the use of Foxy-5 peptide as an anti-metastatic compound. WntResearch AB is about to initiate a phase I study with the Foxy-5 peptide. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","08","Janna Sand-Dejmek","JSD",5,TRUE,3,3,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
